Listed for reference — companies are not ranked in any particular order.
| Market Size 2025 | US$ 21.27 Billion |
| Market Size 2033 | US$ 67.51 Billion |
| CAGR 2026–2033 | 15.53% |
| Segments | By Product/Target Family (HER2-directed ADCs, Nectin-4-directed ADCs, TROP2-directed ADCs) | By Payload Class (Topoisomerase I Inhibitor ADCs, Microtubule Inhibitor ADCs, Others) | By Disease Indication (Breast Cancer, Urothelial Cancer, Lymphoma) |
| Geographies | North America (US, Canada, Mexico) · Europe (Germany, Italy, France, U.K., Spain, Belgium, Netherlands, Luxembourg, Norway, Finland, Denmark, Sweden, Switzerland, Austria, Greece, Portugal, Russia, Poland, Romania, Czech Republic, Ukraine, Slovakia, Bulgaria) · Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Taiwan, Bangladesh) · South and Central America (Brazil, Argentina, Chile, Colombia, Peru) · Middle East and Africa (Saudi Arabia, United Arab Emirates, Kuwait, Bahrain, Qatar, Oman, Turkiye, South Africa, Egypt, Nigeria, Algeria) |
| Deliverables | Historical analysis with CAGR · PEST & SWOT analysis · Market Size at Global, Regional, and Country Levels · Competitive heat map · Company profiles · Excel dataset |
| Report Code | BMIPUB00036699 |
| Lead Analyst | Krishna Sunthwal — Analyst, Research · View Profile |
Gain actionable insights with 350 pages of in-depth Antibody Drug Conjugates Market, including historical trends, 8-year market forecasts, SWOT analysis, competitive landscapes, and downloadable Excel datasets in a single comprehensive package.